Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PHM.0000000000001809 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing diabetic rat peripheral nerve conduction velocity parameters through the potent effects of MitoTEMPO.
Heliyon
December 2024
Baskent University, Faculty of Medicine, Department of Biophysics, Ankara, Türkiye.
The efficacy of MitoTEMPO, a mitochondria-targeted antioxidant, in altering nerve fiber conduction properties within the sciatic nerve of streptozotocin (STZ)-induced diabetic rats, a model for diabetic neuropathy characterized by myelinated fiber atrophy and nodal abnormalities. Utilizing the STZ-induced diabetic rat model, we assessed the impact of MitoTEMPO on nerve function through compound action potential (CAP) analysis and histological evaluation. Key indicators such as maximum depolarization (MD), CAP area, and conduction velocity distribution (CVD) were measured to gauge MitoTEMPO's neuroprotective effects, alongside physical parameters like weight and blood glucose levels.
View Article and Find Full Text PDFDREAM: an adaptive, randomised, placebo-controlled trial of duloxetine for reducing leg pain in people with chronic sciatica-trial protocol.
BMJ Open
December 2024
Institute for Musculoskeletal Health, Sydney Local Health District, Sydney, New South Wales, Australia.
Introduction: Sciatica is a debilitating condition that often becomes chronic, and for which there are few effective treatment options. Treatments such as the anti-depressant duloxetine have shown promise, but the evidence is inconclusive. We are describing a high quality, definitive trial to investigate the efficacy, safety and cost-effectiveness of duloxetine in chronic sciatica.
View Article and Find Full Text PDFLow expression of Frataxin might contribute to diabetic peripheral neuropathy in a mouse model.
Biochem Biophys Res Commun
January 2025
Yancheng Clinical College, Xuzhou Medical University, Yancheng, 224000, PR China. Electronic address:
Diabetes is one of the most prevalent metabolic disorders, and its incidence has been experiencing a steady annual rise in recent years. Diabetic peripheral neuropathy (DPN) represents the most frequent adverse complication, exerting a profound impact on the quality of life for those suffering from diabetes. The etiology of DPN is complex, including impaired mitochondrial function.
View Article and Find Full Text PDFPaclitaxel-induced peripheral neuropathy in male rats attenuated by calmangafodipir, a superoxide dismutase mimetic.
J Pharmacol Sci
January 2025
Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Article Synopsis
- Paclitaxel causes peripheral neuropathy, which limits its dosage, and there aren't currently effective preventative treatments.
- Researchers tested calmangafodipir, a superoxide dismutase mimetic, on male rats to see if it could prevent this nerve damage from paclitaxel.
- The study found that while paclitaxel led to pain sensitivity and nerve damage, calmangafodipir showed protective effects, preventing both symptoms and signs of neuropathy in the rats.
Okanin alleviates symptoms of nociceptive-like responses in diabetic peripheral neuropathy in type 1 diabetic Wistar rats by regulating the AGEs/NF-κB/Nrf-2 pathway.
J Pharmacol Sci
January 2025
Department of Endocrinology, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu, 222000, China. Electronic address:
Elevated reactive species and AGEs contribute to deregulation of transcription factors e.g., NF-κB and Nrf2 in diabetic peripheral neuropathy (DPN).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!